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Abstract
Background: p27 is a cell cycle suppressor gene, whose protein is a negative regulator of cyclin/cdk complexes.
p27 is also a potential target of retinoids in cancer prevention studies. In benign prostate hyperplasia (BPH), and in
most carcinomas, p27
Kip1 is down-regulated, suggesting its potential resistance to retinoids. To test this hypothesis,
we examined the efficacy of 9-cis retinoic acid (9cRA) to suppress prostate cell proliferation (PECP) and
carcinogenesis in p27
Kip1 deficient mice.
Methods: p27
Kip1 deficient (-/-), heterozygous (+/-) and homozygous (+/+) mice were treated for 7 days with
testosterone, 9cRA, or with both, and cell proliferation in dorsolateral prostate (DLP) was determined by BrdU
labeling. Prostate carcinogenesis was induced by N-Methyl-N-Nitrosourea (MNU) and hormone stimulation.
Results: PECP in DLP of two-month-old mice of all genotypes was similar but significantly increased in old p27-/-
mice only. Testosterone treatment increased PECP in all three p27 genotypes with the highest values in p27-/-
mice. p27
Kip1 deficiency did not affect the response of PEC to 9cRA and to 9cRA+testosterone. The decrease of
p27
Kip1 in p27+/- and p27-/- mice progressively increased the incidence and frequency of PIN and tumors. 9cRA
suppressed PIN in all three p27 genotypes and this was associated with decreased PECP and increased cellular
senescence.
Conclusions: This data indicates that p27
Kip1 deficiency promotes prostate cell proliferation and carcinogenesis but
does not affect 9cRA’s potential to suppress prostate carcinogenesis, suggesting that patients with PIN and
carcinomas lacking or having a low level of p27
Kip1 expression may also benefit from clinical trials with retinoids.
Background
Various risk factors, such as race (with black men having
the highest risk), family history, and genetic predisposi-
tion appear to play principal roles in the development
and progression of prostate cancer [1-3]. Over the last
several years, increasing attention has been paid to the
role of p27
Kip1 expression in the development and pro-
gression of various tumors, including prostate cancer.
Human tumors lacking p27
Kip1 appear more malignant
than those with high levels of the gene’s expression [4,5].
Normal prostate epithelial cells (PEC) exhibit abundant
amounts of p27
Kip1 protein and mRNA, whereas in
benign prostate hyperplasia (BPH) p27
Kip1 decreases to
undetectable levels. In cont r a s tt oB P H ,m o s tp r o s t a t e
carcinomas contain p27 mRNA but low to undetectable
levels of p27
Kip1 protein, suggesting post-transcriptional
alterations in the gene’s activity [6,7]. Little is known
regarding when in the course of prostate carcinogenesis
disassociation between p27 mRNA and protein expres-
sion occurs or whether p27
Kip1 alone or in cooperation
with other genes is involved in mediating the response of
prostate pre-malignant and tumor cells to various che-
mopreventive and antitumor agents.
p27
kip1 is a cell cycle suppressor gene, whose protein
product is a negative regulator of cyclin dependent
kinases (CDKs) [8-10]. Cyclin dependent kinases-2/4/6
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ing complexes that are variably expressed during the
cell cycle. When inhibited by p27
Kip1,p 2 1
Wef1/Cip1,o r
p16
Ink4a, CDKs can suppress cell cycle progression by
modulating pRb phosphorylation, leading to inhibition
of E2F transcription factors and further to suppression
of DNA replication [11,12]. p27
Kip1 may also cooperate
with other cell cycle suppressor genes and thus further
inhibit cell proliferation and carcinogenesis [13,14]. For
example, 100% of mice deficient in both p27
Kip1 and
PTEN (phosphatase and tensin homolog deleted from
chromosome 10) (PTEN +/-; p27-/-) developed prostate
tumors within 4-6 months vs. 50% of those with the
PTEN mutation only [15-17]. Recently, Besson et al.
[18] discovered an oncogenic activity of p27
Kip1 that
causes stem cell expansion and a multiple tumor pheno-
type. They generated a knock-in mouse in which four
amino acid substitutions in the CDKN1b gene product
prevented its interaction with cyclins and CDKs
(p27
CK*) and found tumors in multiple organs, includ-
ing: lung, pituitary, retina, adrenals, ovary, spleen, and
lymphomas. No data has been published on the effects
of p27
Kip1 deficiency on chemically-induced prostate
carcinogenesis and on the sensitivity of PEC to retinoids.
Studies from the Fero et al. [19] group have shown
that p27-/- and, to a lesser extent, p27+/- mice are
more susceptible than p27+/+ mice to radiation and
chemically induced carcinogenesis. They have found
that partial reduction in p27 expression in p27+/- mice
can also sensitize cells in a tissue specific manner to
undergo malignant transformation. However, they did
not examine prostate glands (personal communication).
In human tumors haplo-insufficiency is not a frequent
phenomenon. However, a moderate decrease in protein
expression of certain tumor suppressors, including
p27
Kip1, may also promote the neoplastic process [20].
Most chemopreventive and antitumor agents, including
retinoids, affect normal and tumor cells by inhibiting cell
proliferation, and this has been associated with increased
expression of cell cycle suppressors [21]. It has been sug-
gested that retinoids which induce cell differentiation
and suppress cell proliferation can up-regulate p27
kip1
and thereby inhibit cell cycle progression [22]. Others
[23] and we [24] recently observed that 9cRA can sup-
press prostate carcinogenesis when given to rats treated
with a carcinogen or to transgenic mice that sponta-
neously develop prostate tumors [25]. Our previous stu-
dies on Noble rats revealed that, among various retinoids,
9cRA but not 4-(Hydroxyphenyl) retinamide (4-HPR)
reduced the incidence and multiplicity of prostate intrae-
pithelial neoplasia (PIN) [24]. The molecular mechanisms
involved in inhibition of prostate carcinogenesis by 9cRA
and other retinoids are poorly understood. 9cRA is a
ligand of both retinoic acid receptors (RARs a,b,g)a n d
retinoid × receptors (RXRs a,b,g), suggesting receptor
dependent mechanisms of cell and tumor growth inhibi-
tion [22]. However, retinoids may also affect normal and
tumor cells by receptor independent pathways [26,27].
In this study we assessed the role of p27 deficiency on
prostate cell proliferation, response to hormonal stimula-
tion, and to treatment with retinoids. We also examined
whether p27
Kip1 deficiency may affect MNU-induced
prostate carcinogenesis and the efficacy of 9cRA in sup-
pressing the neoplastic process. We found that p27
Kip1
deficiency promotes prostate cell proliferation and carci-
nogenesis but does not affect the efficacy of 9cRA in sup-
pressing PIN and tumor development.
Methods
Mice
p27+/+, p27+/- and p27-/- mice were generated in our
lab by crossbreeding p27+/- female with p27-/- male
mice. p27 deficient mice (+/- and -/-) were obtained
from Kiyokawas’ lab and have been developed based on
t h ec 5 7 B L / 6m o u s eb a c k g r o u n d .M o u s eg e n o t y p ew a s
assessed by PCR using DNA isolated from small tail tis-
sue samples when the animals were 14 days old, as
described previously [28]. For the long-term carcinogen-
esis study, male p27+/+, p27+/- and p27-/- mice were
followed for up to 12 months. Most p27-/- mice died
from pituitary and intestinal tumors at the age of 7 to
12 months, as has been reported previously [19,28]. The
animals were housed at the Biology Research Laboratory
at the University of Illinois, Chicago, and their breeding
and treatment were conducted according to the require-
m e n t sl i s t e di nt h eG u i d ef o rt h eC a r ea n dU s eo f
Laboratory Animals issued by the University’sA n i m a l
Care Committee. Animals had free access to water and
food, Teklad 4% Purina mouse/rat diet (Harland Teklad,
Madison, WI).
Hormone stimulation of prostate cell proliferation
Two separate studies were performed. In the short-term
study, two-month-old mice of all three p27 genotypes
were treated for 7 days with testosterone (Sigma Chem.
Co., St. Louis) mixed in purified sesame oil. Each animal
received 3 sc injections of testosterone, 1.0 mg/kg body
weight, 2 days apart in a volume of 0.1 ml. In the long-
term chemoprevention study, two experiments were per-
formed. In the first, two-month-old p27+/+, p27+/- and
p27-/- mice were first treated with testosterone, as
described above, and then, on the sixth day after initia-
tion of hormone stimulation, MNU was injected ip. In
the second chemoprevention experiment, mice were
first sc implanted with a testosterone pellet (12.5 mg/
pellet: Cat No: SA-151, Innovative Research of America,
Saratoga, FL). Six days later the animals were ip injected
with MNU to initiate the neoplastic process. Four days
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an estradiol pellet (0.18 mg/pellet: Cat No: SE-121,
Innovative Research of America, Saratoga, FL), aiming
to further stimulate PEC proliferation, as was reported
previously [23,24]. However, in the second experiment,
within four weeks, about 50% of p27+/- and p27-/- ani-
mals developed severe prostate hypertrophy, leading to
almost complete obliteration of urethra, causing urine
retention in the bladder and death by kidney failure.
Carcinogen
N-Methyl-N-Nitrosourea (MNU), was obtained from Ash
Stevens Inc. (Detroit, MI), dissolved in sterile acidified
saline (pH 5.0), and injected ip at 30 mg/kg body weight
six days after sc testosterone treatment or implantation
of testosterone pellets. At that time, the number of prolif-
erating PEC sharply increased (see Table 1), suggesting
that a high number of proliferating cells would facilitate
MNU-induced prostate carcinogenesis.
9-cis retinoic acid (9cRA) was obtained from the
repository of the National Cancer Institute. It was sus-
pended in purified sesame oil (vehicle) and given by
gavage by #20 gauge needle in 0.1 ml 6 days a week at a
concentration of 30 mg/kg body weight. For the long-
term chemoprevention study, 9cRA was mixed in the
diet at 50 mg/kg.
Histomorphology
Mouse prostate consists of 3 glands: dorso-lateral (DLP),
anterior (AP, coagulating gland) and ventral prostate
(VP). Seminal vesicles were also macroscopically exam-
ined as part of the prostate tissue complex. During
autopsy all the above glands were removed, separated
under a dissection microscope from the urinary bladder
and urethra, fixed in 10% formalin, and embedded in par-
affin [29]. DLP and AP were cut longitudinally through
the urethral part of the prostate and both tissue pieces
were put in the cassette with the cutting area facing
down. Stepwise, 4 μm thick paraffin sections at three
separate tissue levels 30 μm apart were cut. On each slide
3 tissue sections were mounted. All resulting slides were
labeled consecutively. This method of embedding and
sectioning has proved to be essential for detecting small
lesions and micro invasive carcinomas and accurately
tracing their origin and structural characteristics.
RARa and RXRa expression
Both receptors were determined by immunocytochemis-
try employing, respectively, anti-RARa (SC-551, Santa
Cruz Biotech.) and anti-RXRa (SC-553) antibodies and
ABC kit. Only cells with staining localized in the
nucleus were considered positively stained.
Proliferating cells
In the short-term study, proliferating cells were identi-
fied by BrdU-labeling. Two hrs prior to sacrifice, mice
were ip injected with 5-Bromodeoxyuridine (BrdU),
50 mg/kg body. BrdU-labeled cells were detected by
their corresponding antibody (Santa Cruz Biotech. Inc.,
CA) and ABC kit, as we reported previously [28]. In the
long-term cancer prevention study, proliferating cells
were identified at the end of experiment by Ki-67 anti-
body (Santa Cruz Biotech. Inc.) and ABC-kit.
Apoptosis
Apoptotic cells were identified on parallel tissue sections by
TUNEL assay, as recommended by the ApopTag in situ
hybridization detection kit (Oncor, Co., Gaithersburg,
MD). Tissue sections were counterstained by methyl green
for visualization of tumor morphology.
Senescent cells
An SA-b-Gal activity assay was employed to identify
senescent cells in prostate tissues and tumors [30]. Fro-
zen sections (5-7 μmt h i c k )f r o mc o n t r o la n dc e l l st r e a -
ted with 9cRA were fixed in 3.0% formaldehyde for
5 min, washed in PBS, and stained in b-Gal (5-bromo-4-
chloro-3-indolyl-b-D-galactosidase) (Sigma Chem., Co.
St. Louis, MO) solution at pH 6.0 for 24 hrs at 37°C.
Statistical analysis
Differences in the incidence of prostate lesions among
various groups were evaluated by the ANOVA test fol-
lowed by the LSD test. Differences in the average
Table 1 Effects of testosterone and 9cRA on cell proliferation in DLP
Controls 9cRA Testosterone Testosterone+9cRA
Genotype No BrdU (%) No BrdU (%) No BrdU (%) No BrdU (%)
p27+/+ 5 0.3 ± 0.2 6 0.3 ± 0.2 5 0.7 ± 0.3 ** 6 0.7 ± 0.3 **
p27+/- 6 0.3 ± 0.2 5 0.5 ± 0.4 8 1.5 ± 0.6* ** 6 1.4 ± 0.5* **
p27-/- 6 0.4 ± 0.2 6 0.5 ± 0.3 9 1.7 ± 0.3* ** 5 1.5 ± 0.3* **
Two-month-old p27+/+, p27+/-, and p27-/- mice were treated for 7 days with: placebo (sesame oil-control group); 9cRA, 30 mg/kg body weight; testosterone, 1.0
mg/kg body weight; or combination of 9cRA + testosterone. BrdU, at 50 mg/kg body weight was injected 2 hrs prior to animal’s sacrifice. BrdU-labeled cells were
evaluated among epithelial cells of DLP by counting at least 500 cells per animal. Two to three levels of sectioning, 30 microns apart, were employed in some
animals to reach the above number of cells. The evaluation of BrdU-labeled cells was done blindly, without knowledge of the animals’ genotype and the
treatment protocol. No, number of animals in each group; *, significant difference (p < 0.05) as compared to the values in p27+/+ mice; **, significant difference
(p < 0.05) as compared to control values.
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l o w e db yu n p a i r e dS t u d e n t ’s T-test. SAS software was
used for statistical analysis. Differences with p < 0.05
were considered significant.
Results
p27
Kip1 deficiency increases prostate epithelial cell
proliferation
To determine whether the decrease of p27
Kip1 in both p27
heterozygous and p27 deficient mice may affect PEC pro-
liferation, two-month-old p27+/+, p27+/- and p27-/- mice
were injected ip with BrdU two hrs prior to sacrifice and
proliferating cells identified by a corresponding anti-BrdU
antibody. DLP was predominantly examined, because
most PIN and carcinomas in human prostate develop in
tissue areas relevant to DLP of mice. As shown in Table 1,
the percentage of BrdU-labeled cells in DLP of mice with
the above p27 genotypes is very low (< 0.5%), lacking any
significant difference in the values between them. 9cRA at
30 mg/kg body weight given for 7 days by gavage did not
significantly affect proliferation of normal PEC. Since tes-
tosterone plays a significant role in the development and
progression of human prostate cancer, we determined
whether p27
Kip1 deficiency may affect testosterone-
induced cell proliferation. Two-month-old p27+/+,
p27+/- and p27-/- mice were treated for 7 days with pla-
cebo, testosterone, or a combination of testosterone +
9cRA, and BrdU-labeled cells were determined (Table 1).
In testosterone-treated animals, BrdU-labeled cells
increased in all three p27 genotypes; the most significant
increases were in p27+/- and p27-/- mice, from 0.3 ± 0.2%
(placebo) to 1.5 ± 0.6% (p < 0.02) in the former and from
0.4 ± 0.2% (placebo) to 1.7 ± 0.3% (p < 0.001) in the latter.
The values of BrdU-labeled cells in testosterone-treated
animals were significantly higher in p27+/- and p27-/-
mice than in p27+/+ mice. This data indicates that either
p27 haplo-insufficiency or p27 deficiency can promote tes-
tosterone-induced cell proliferation. In animals treated
with testosterone + 9cRA, the values of BrdU-labeled cells
were close to those of animals treated with testosterone
only and there was no significant difference between them
for all three p27 genotypes. However, proliferating cells in
p27+/- and p27-/- treated with testosterone + 9cRA were
higher than those in p27+/+ mice (Table 1), further indi-
cating that p27 deficiency can promote proliferation of
prostate epithelial cells.
p27
Kip1 deficiency promotes prostate carcinogenesis
To assess the role of p27 deficiency on prostate carcino-
genesis, p27+/+, p27+/- and p27-/- mice at the age of two
months were sc injected with testosterone, as described
previously, to stimulate cell proliferation, and six days
latter MNU was administered ip to initiate the neoplastic
process. Four days after MNU administration, the animals
were randomized in control (MNU-treated) and 9cRA-
treated (MNU+9cRA) groups. The latter animals were
treated with 9cRA as long as they remained alive. Most
p27-/- mice died at the age of 7 to 12 months primarily
from pituitary and other tumors: intestinal, kidney, thymus.
Therefore, the incidence and frequency of PIN and tumors
in all three genotypes were examined and compared within
this time frame. Male p27-/- mice at the end of the study
were larger in size as compared to p27+/+ mice, whereas
p27 +/- mice had intermediate body weight (Table 2). The
weight of DLP also increased in p27+/- and further
increased in p27-/- mice as compared to p27+/+ mice:
from 48.3 ± 13.1 mg in p27 +/+ to 67.2 ± 14.5 mg in
p27+/- to 97.6 ± 21.0 mg (p < 0.01) in p27-/-. MNU alone
induced PIN in all three p27 genotypes (Table 3). PIN was
detected the most in DLP (Fig. 1A-B), where intraductal
(Fig. 1C) and invasive (Figs. 1D-arrows) carcinomas were
also identified. The incidence and multiplicity of PIN pro-
gressively increased, respectively, from 11% and 0.16 ± 0.5
in p27+/+ to 60% and 1.5 ± 0.5 (p < 0.05) in p27+/-, and
further to 70% and 2.0 ± 0.4 in p27-/- (p < 0.005) mice
(Table 3). Multiplicity of PIN in p27-/- mice was also
higher as compared to that in p27+/- mice (p < 0.01). In
addition to PIN in DLP, MNU also induced tumors in dis-
tant organs (DO): (pituitary, thyroid, lymph node, intestine)
of both p27+/- and p27-/- mice.
9cRA suppresses prostate carcinogenesis irrespective of
p27
Kip1 expression
Treatment of animals with 9cRA for 7-12 months
reduced by 10-15% the body weight of all three p27
genotypes, with lack of significant difference between
control, placebo-treated and 9cRA-treated animals
(Table 2). 9cRA did not significantly decrease DLP
weight in p27+/+ and p27+/- mice, but reduced DLP
weight in p27-/- mice, from 97.6 ± 21.0 mg in placebo
to 80.5 ± 18.6 mg (p < 0.02) in 9cRA-treated mice
(Table 2). 9cRA reduced PIN in all three p27 genotypes.
Thus, in p27+/+ mice PIN decreased from 11% for inci-
dence and 0.16 ± 0.5 for frequency in placebo-treated to
zero in 9cRA-treated animals. In these animals no pros-
tate or distant tumors were detected (Table 3). 9cRA
was also efficacious in both p27+/- and p27-/- mice. In
p27+/- mice, 9cRA decreased PIN from 1.5 ± 0.4 (pla-
cebo) to 1.1 ± 0.6 (p < 0.05), and in p27-/- mice from
2.0 ± 0.4 (placebo) to 1.4 ± 0.4 (p < 0.005). 9cRA appar-
ently was not efficacious and did not reduce the number
of tumors in distant organs (Table 3).
9cRA was unable to suppress hormone-induced prostate
carcinogenesis
We also determined whether testosterone + estradiol
hormone stimulation might promote MNU-induced car-
cinogenesis in p27 deficient mice and affect the
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others [23] and we [24] have shown that the combina-
tion of carcinogen + testosterone + estradiol stimulates
prostate carcinogenesis in rats. For this study, a testos-
terone pellet was first sc implanted to simulate cell pro-
liferation and 6 days later the animals were injected
with MNU to initiate prostate carcinogenesis. Four days
after carcinogen administration an estradiol pellet was
sc implanted. Both testosterone and estradiol pellets
were designed to release hormones within 60 days, with
a second and third pellet projected to be implanted after
those initial 60 days. However, testosterone + estradiol
treatment induced severe prostate hypertrophy, predo-
minantly in p27-/- and p27+/- mice, with complete
blockage of urethra that caused urine retention in the
bladder, and about 50% of animals died within 4-6
weeks due to kidney failure and intoxication. Therefore,
the number of animals in individual groups at the end
of the experiment (Table 4) is relatively small, as com-
pared to 20 animals per group at the beginning of the
experiment. The experiment continued with surviving
animals, and no second or third pellets were implanted.
As shown in Table 4, PIN was identified in all p27 gen-
otypes, with the lowest value in p27+/+ (1 in 15
animals), and its incidence and frequency increased in
p27+/- (40% for incidence and 0.7 ± 0.3 for frequency)
and progressed further in p27-/- mice (80% for inci-
dence and 2.3 ± 1.2 (p < 0.05) for frequency). Tumors
localized in prostate and distant organs (DO) were also
detected in p27+/- (No: 7) and in p27-/- (No: 10) mice.
Treatment of animals with 9cRA was less efficacious
than in animals not undergoing hormone stimulation.
Thus, the incidence of PIN was similar in placebo- and
9cRA-treated p27+/+ and p27-/- mice, 13% in both pla-
cebo groups and 40% and 60% in treated animals,
respectively (p < 0.5); even in 9cRA-treated mice a ten-
dency for increase of PIN multiplicity was observed, ris-
ing from 0.7 ± 0.3 in placebo to 1.5 ± 1.1 (p < 0.1). In
p27-/- mice hormone stimulation for 60 days further
increased PIN multiplicity (2.3 ± 1.2 per animal) as
compared to p27+/+ and p27+/- mice, but 9cRA was
again not efficacious in suppressing the neoplastic pro-
cess (Table 4).
9cRA inhibits prostate cell proliferation and induces
cellular senescence
Since 9cRA can modulate cell growth by retinoid recep-
tor dependent and independent mechanisms, RARa and
RXRa were also determined by ICH. These two recep-
tors are chief targets of 9cRA in epithelial cells [22]. As
shown in Fig 1G, RARa is expressed in prostate epithe-
lial cells of non-PIN (right gland), as well as in the
papillary structures of PIN (left gland, arrow); note the
nuclear RARa location. RXRa was also detected in
almost all PIN cells (Fig. 1H, arrow). An attempt was
made to compare the percentage of RARa and RXRa in
placebo- and 9cRA-treated animals, but no difference
was found (data not presented), suggesting a receptor
independent mechanism of cell growth inhibition. To
further understand whether 9cRA suppresses prostate
carcinogenesis by inhibiting cell proliferation or/and by
inducing apoptosis and/or cellular senescence (CS),
mice treated with MNU and MNU + 9cRA (Table 3)
were sacrificed at the end of the experiment, DLP and
AP were frozen on dry ice, and then frozen tissue sec-
tions were prepared and treated with SA-b-Gal kit for
identification of senescent cells. Cell proliferation was
determined on frozen sections by Ki-67 antibody
Table 3 9cRA inhibits MNU-induced prostate
carcinogenesis in p27 deficient mice
PIN P Tumors
Genotype Animals
No
9cRA Incidence Frequency P DO
p27+/+ 18 0 11 0.16 ± 0.5 0 0
p27+/+ 17 + 0 0 0 0 0
p27+/- 16 0 60 1.5 ± 0.5* 3 4
p27+/- 15 + 44 1.1 ± 0.6 0.05 2 4
p27-/- 15 0 70 2.0 ± 0.4* 3 6
p27-/- 15 + 53 1.4 ± 0.5 0.005 4 6
Animals were treated with MNU, 30 mg/kg body weight at the age of 2
months and followed until sacrifice between 7-12 months of age. PIN were
identified in DLP by cutting longitudinally through the urethral part of the
prostate. H&E staining was used for identification of PIN. Stepwise, 4 μm thick
paraffin sections at three separate tissue levels 30 μm apart were cut and the
number of PIN per prostate determined. Incidence, percentage of animals
with PIN per group; frequency, number of PIN per animal. PIN were
determined in various groups without knowledge of the treatment protocol.
(P), prostate; (DO), distant organs; *, significant difference (p < 0.01) in the
multiplicity of PIN between p27+/- and p27-/- mice.
Table 2 Alteration in body weight and in DLP weight in the course of prostate carcinogenesis
Genotype Body wt: (g)
Placebo
Body wt. (g)
9cRA
DLP-(mg)
Placebo
DLP-(mg)
9cRA
p27+/+ 8 30.8 ± 4.3* 10 27.2 ± 5.4* 48.3 ± 13.1** 45.6 ± 7.7**
p27+/- 10 35.8 ± 5.1 12 31.3 ± 5.6 67.2 ± 14.5 60.2 ± 10.5
p27-/- 12 41.4 ± 5.6* 10 35.5 ± 6.4* 97.6 ± 21.0** x 80.5 ± 18.6** x
These are the final measurements of body weight (g) at the end of experiment when the animals were sacrificed. DLP was isolated at autopsy, measured on an
analytical balance and then frozen or embedded in 10% neutral formalin. Body and DLP weights were higher in p27-/- as compared to p27+/+ mice; *, p < 0.01;
**, 0.001. 9cRA also decreased DLP weight in p27-/- mice (x) as compared to placebo-treated mice (p < 0.02).
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Page 5 of 12Figure 1 Morphological changes in DLP of p27 deficient mice in the course of carcinogenesis. 1A: Dorso-lateral prostate of 6-month-old
p27-/- mice. Note the glandular structures are covered by a single layer of prostate epithelial cells (PEC). Glands are surrounded by a thick layer
of myoepithelial cells, stroma cells and collagen (arrows). H&E staining × 200. 1B: High grade PIN in a p27-/- mice treated with MNU and
sacrificed at the age of 9 months. Hyperplastic and dysplastic PEC cover entire glands and form papillary and alveolar structures (arrows). The
surrounding connective tissue stroma is very abundant (arrow had). H&E × 200. 1C: Ductal carcinoma of papillary type in DLP of a p27-/- animal
treated with MNU and sacrificed at the age of 10 months. Note, tumor cells occupy the entire glands lumen. H&E × 200. 1D: Infiltrative prostate
carcinoma in a p27-/- animal sacrificed at the age of 12 months. Tumor cells infiltrate the surrounding stroma (arrows). H&E × 200. 1E: Pituitary
tumor in a p27-/- mice sacrificed at the age of 10 months. H&E × 200. 1F: Intestinal carcinoma in a p27-/- mice sacrificed at the age of 9
months. Note tumor cell infiltration in the surrounding stroma (arrow). H&E × 200. 1G: RARa expression in DLP of a 6-month-old p27+/- mice.
RARa was detected by anti-RARa antibody (SC-251) and ABC kit. The receptor is expressed in papillary structures (arrow) and in the basal layer
of epithelial cells. The slide is counterstained by hematoxylin × 200. 1H: RXRa expression in PIN of p27-/- 9-month-old mice. Note that most
epithelial cells express RXRa receptor (arrow). The slide is counterstained by hematoxylin × 200.
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associated with PIN in p27+/- and p27-/- control (pla-
cebo-treated) mice are close, with a lack of statistical
difference between them: 1.4 ± 0.3% vs. 1.7 ± 0.8% (p >
0.5), respectively (Table 4). In PIN of p27-/- mice, Ki-67
values are much higher as compared to those of p27+/-
mice: 4.6 ± 1.4% vs. 2.6 ± 0.4% (p < 0.005), respectively.
9cRA was not efficacious and did not affect proliferating
cells in glandular structures not associated with PIN
(Fig. 2B). However, 9cRA decreased Ki-67 positive cells
in PIN of both p27+/- and p27-/- mice from 2.6 ± 0.4%
(placebo) to 1.5 ± 0.5% (p < 0.01) and from 4.6 ± 0.4%
(placebo) to 3.5 ± 0.5% (p < 0.001), respectively. Apop-
tosis was rare in both PIN and non-PIN epithelial cells
of placebo-treated animals and 9cRA did not affect their
number (Table 5). Surprisingly, a high percentage of
senescent cells was found in PIN and non-PIN prostate
epithelial cells of both placebo- and 9cRA-treated mice
(Fig. 2E-H). 9cRA induced CS in non-PIN epithelial
cells of both p27+/- and p27-/- mice: from 0.8 ± 0.4% in
placebo to 2.7 ± 1.3% in 9cRA treated for p27+/- mice
and from 1.2 ± 0.4% in placebo to 2.4 ± 0.5% in 9cRA-
treated p27-/- mice. 9cRA also induced CS in PIN of
both p27+/- and p27-/- mice: from 1.0 ± 0.5% in pla-
cebo to 4.8 ± 1.2% in 9cRA-treated p27+/- mice (p <
0.001) and from 3.2 ± 0.7% in placebo to 6.8 ± 2.2%
(p < 0.001) in 9cRA-treated p27-/- mice (Fig. 2G-H).
Discussion
The main goal of this study was to determine whether
p27 deficiency in p27+/- and p27-/- mice may affect
PEC proliferation and carcinogenesis, as well as the effi-
cacy of 9cRA in suppressing the neoplastic process. p27
heterozygous (+/-) and p27 null (-/-) mice were selected
for the following reasons: a) the difference in p27
Kip1
expression between p27+/+, p27+/- and p27-/- mice
simulates the gene’s alterations in the course of prostate
cancer development in humans, as p27
Kip1 is expressed
in normal PEC, lacking in BPH, and differentially
expressed in malignant tumors [4,8]; b) p27-/- mice
develop predominantly hyperplastic and premalignant
(PIN) lesions, which are much easier to suppress by can-
cer preventive agents, like retinoids, than aggressively
growing carcinomas such as those in PTEN mice
[15-17]; c) previous studies have shown that p27 haplo-
insufficiency promotes carcinogen- and radiation-
induced tumors in various organs [19,20]; d) retinoids
are efficacious inhibitors of prostate carcinogenesis in
animal models [23,24]; and e) p27
Kip1 is involved in
mediating the effect of retinoids on PEC both in vitro
and in vivo [25-27]. Here, we confirmed two of our pre-
vious observations [28,31] and those of others [32-35].
First, we confirmed that p27-/-mice are larger than p27
+/+ mice, whereas heterozygous p27+/- mice have an
intermediate body weight (see Table 2). The increase in
body weight in p27-/- mice was due to generalized orga-
nomegaly with disproportional enlargement of the
spleen, thymus, testis, ovaries, pituitary gland (data not
shown). Second, we confirmed that old (> 7-12 months)
p27-/- and p27+/- mice develop spontaneous hyperpla-
sia and adenomas in the intermediate pituitary lobe,
intestine, kidney and thymus that lead to the animals’
death. The data generated in this study indicates that
under normal physiological conditions, PEC prolifera-
tion in two-month-old mice is similar in all three p27
genotypes (Table 1). However, when the values of prolif-
erating cells were compared in 9- to12-month-old mice,
proliferating cells were much higher in p27-/- and
p27+/- than in p27+/+ mice, suggesting that p27
absence or insufficiency promotes PEC proliferation in
the aging animals where hyperplastic and pre-malignant
lesions occur (Table 5). This data supports previous stu-
dies from Cardon-Cardo’s group [7], which found higher
PEC proliferation (Ki-67 labeling) in p27 null (-/-) mice
as compared to p27+/+ mice. However, they did not
provide information whether p27 heterozygous and null
mice develop PIN and whether the frequency of PIN
could be regulated by hormone stimulation or cancer
prevention agents. Thus, it appears that the loss of
p27
Kip1 keeps a high base level of PEC proliferation in
old animals that leads to development of hyperplastic,
pre-malignant and malignant lesions. When PEC prolif-
eration was stimulated by testosterone, a much higher
proliferative response was observed in p27+/- and
p27-/- than in p27+/+ mice, indicating that p27
Kip1 lack
or haplo-insufficiency increases the sensitivity of PEC to
hormone stimulation. This information is important,
because there are sufficient clinical data showing that an
increased testosterone circulation level in men is
Table 4 Incidence and frequency of PIN and tumors in
mice treated with MNU + testosterone + estradiol
Genotype 9cRA Animals-No PIN P Tumors*
No
at
start
at
end
Incidence Frequency
p27+/+ 0 20 15 13 0.13 ± 0.3 2
p27+/+ + 20 15 13 0.13 ± 0.3 ns 1
p27+/- 0 20 10 40 0.7 ± 0.3 4
p27+/- + 20 10 60 1.3 ± 1.1 ns 3
p27-/- 0 20 10 80 2.3 ± 1.2 5
p27-/- + 20 8 87 1.7 ± 1.0 ns 5
Animals were implanted with a testosterone pellet at the age of 2 months
and 6 days later MNU was injected ip to initiate the neoplastic process. Four
days after carcinogen administration an estradiol pellet was sc implanted. %,
incidence of tumors among control and treated animals; No: multiplicity of
PIN per treated animal; ns, not significant (p > 0.05). To determine the
incidence (%) and frequency of PIN in DLP, 4 μm thick longitudinally paraffin
sections through the urethral part of the prostate were cut stepwise at three
separate levels 30 μma p a r t .
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Page 7 of 12Figure 2 Effects of 9cRA on cell proliferation and senescence in DLP of p27 deficient mice. Fig. 2A: Cell proliferation, as determined by
Ki-67 antibody in DLP of 9-month-old p27+/+ mice. Note several Ki-67-positive cells (brawn-stained, arrows) in glandular structures which are
covered by a single layer of epithelial cells. The slide is counterstained by hematoxylin × 200. 2B: Ki-67 positive cells (arrows) in anterior (large
left) and DLP (two right glands) of 9-month-old p27-/- mice. Note the thick connective tissue surrounding glandular structures. The slide is
counterstained by hematoxylin × 200. 2C: Ki-67 positive cells in PIN of MNU-treated mice. The number of Ki-67 positive cells is higher (arrow), as
compared to those in Fig. 2B. The slide is counterstained by hematoxylin × 200. 2D: Treatment of p27-/- mice with 9cRA for 6 months reduced
the number of Ki-67 positive cells in PIN (arrow). Note the inflammation associated cells in PINs’ lumen. The slide is counterstained by
hematoxylin × 200. 2E: Senescent cells (blue stained) determined by SA-b-Gal staining in glandular and ductal structures of DLP of 9-month-old
p27+/- mice. Senescent cells are also detectable among myoepithelial and stroma cells (arrows). The slide is counterstained by nuclear fast red ×
200. 2F: Treatment of animals with 9cRA increased senescent cells (blue stained) in DLP and AP of a p27+/- mice. The slide is counterstained by
nuclear fast red × 200. 2G: 9cRA increased senescent cells in low grade PIN (arrows) as compared to non-PIN areas of a 10-month-old p27+/-
animal. The slide is counterstained by nuclear fast red × 200. 2H: 9cRA also increased senescent cells in high grade PIN as shown in the right
glandular structure. The slide is counterstained by nuclear fast red × 200.
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Page 8 of 12associated with increased risk in developing prostate
cancer [16]. Therefore, temporary or continuous down-
regulation of p27
Kip1 expression in PEC may promote
the effect of testosterone or other growth factors in sti-
mulating prostate carcinogenesis.
In a previous study Fero et al. [19] reported that p27
Kip1
protein expression was lacking in p27-/- mice, decreased
by 50% in p27+/- mice, and promoted radiation and che-
mical-induced (N-Ethyl-N-Nitrosourea-ENU) carcinogen-
esis. In p27-/- mice, tumors developed in the lung,
intestine, pituitary, ovary, and endometrium earlier and at
a higher frequency as compared to both p27+/- and p27
+/+ mice. However, in Fero’s study prostate and male
reproductive organs were not examined at the tissue level
(personal communication) and neither PEC proliferation
was stimulated by testosterone. In another study, Di Cris-
tofano et al. [15] reported on cooperation between p27
Kip1
and PTEN in developing PIN and prostate cancer. PTEN
is a tumor suppressor and its activity leads to the induc-
tion of p27
Kip1; therefore, the lack or down-regulation of
PTEN may suppress p27
Kip1 expression and thus promote
cell proliferation and carcinogenesis. Concomitant inacti-
vation of one PTEN allele and one or both p27 alleles in
transgenic mice accelerates the development and pro-
gression of prostate and other malignancies [16,17]. We
did not use PTEN+/-, p27-/- mice in this study because
tumors in the prostate and other organs develop very
early, within 3 months after birth, and most animals die
at the age of 16-20 weeks. This very aggressive neoplas-
tic process is difficult to modulate with retinoids and
other cancer prevention agents. We found that the pro-
gressive decrease of p27
Kip1 expression in p27+/- and
further in p27-/- mice promotes MNU-induced prostate
carcinogenesis (Table 3). It appears that there is a negative
correlation between the level of p27
Kip1 expression and the
incidence and multiplicity of PIN and prostate tumors.
Since most animals were sacrificed between 9 and 12
months of age, this time period is probably not sufficient
for PEC in p27+/+ mice to transform in PIN and progress
in invasive carcinomas. For instance, studies on rats trea-
ted with MNU have shown that prostate pre-malignant
lesions and carcinomas occur 12 to 18 months after carci-
nogen administration [23,24]. To accelerate prostate carci-
nogenesis, we treated p27+/+, p27+/- and p27-/- mice
with MNU and stimulated PEC proliferation by testoster-
one + estradiol releasing pellets (Table 4). Previous studies,
including ours, have shown that testosterone + estradiol
stimulate PEC proliferation [35] and carcinogenesis in rats
[23,24]. However, because of the severe prostate hypertro-
phy with complete urethra blockage in some animals and
high death rate, the study continued with surviving ani-
mals only. Hormone stimulation was more efficacious in
inducing PIN and tumors in p27+/- and p27-/- mice than
in p27+/+ mice, suggesting that deregulation of p27
Kip1
expression in PIN may promote hormone mediated pros-
tate carcinogenesis in men. The data for multiplicity of
PIN in Table 3, where MNU was only used to induce
prostate carcinogenesis, are close to those in Table 4,
where MNU + testosterone + estradiol were employed.
This can be explained by termination of hormone stimula-
tion which occurs 60 days after pellet implantation and
which may cause cell death and thereby eliminate trans-
formed PEC and their potential progression towards PIN
and tumors.
What is most interesting from this study was that
9cRA suppressed MNU-induced prostate carcinogenesis
Table 5 9cRA inhibits cell proliferation (Ki-67) and induces senescent phenotype in PIN
Genotype Animals Cell Type 9cRA Ki-67% p Apo-% p Sen-% p
p27+/+ 5 PEC 0 0.8 ± 0.3* 0.4 ± 0.2 0.8 ± 0.4
p27+/+ 6 PEC + 0.6 ± 0.4 ns 0.6 ± 0.2 1.1 ± 0.5
p27+/+ 5 PIN 0 1.2 0.3 0.9
p27+/+ 5 PIN + NA NA NA
p27+/- 6 PEC 0 1.4 ± 0.4* ** 0.01 0.3 ± 0.2 0.8 ± 0.4
p27+/- 6 PEC + 1.2 ± 0.5 ns 0.4 ± 0.2 ns 2.7 ± 1.3 0.001
p27+/- 5 PIN 0 2.6 ± 0.4 0.6 ± 0.3 1.0 ± 0.5
p27+/- 6 PIN + 1.5 ± 0.5 0.001 0.5 ± 0.4 ns 4.8 ± 1.2 0.001
p27-/- 6 PEC 0 1.7 ± 0.5* ** 0.3 ± 0.2 1.2 ± 0.4
p27-/- 5 PEC + 1.6+0.7 ns 0.4 ± 0.2 ns 2.5 ± 1.3 0.001
p27-/- 6 PIN 0 4.6 ± 0.4 0.6 ± 0.3 3.2 ± 0.7
p27-/- 5 PIN + 3.5 ± 0.5 0.001 0.5 ± 0.4 ns 6.8 ± 2.2 0.001
The above data were obtained from placebo- and 9cRA-treated animals at the time of their sacrifice at 9-12 months of age. PEC, prostate epithelial cells from
DLP not associated with PIN; 0, Placebo-treated animals; +, animals treated with 9cRA; PIN (low and high grade) was identified in H&E stained slides. To
determine the incidence (%) and frequency of PIN in DLP and AP, 4 μm thick paraffin sections were cut longitudinally through the urethral part of the prostate
stepwise at three separate levels 30 μm apart. All resulting slides were labeled consecutively. Proliferating cells were detected by Ki-67 antibody (Ki-67); Cells in
apoptosis (Apo-%) were detected by ApopTag kit based on the TUNEL assay; Cells in senescence (Sen-%) were identified by SA-b-Gal staining employing a kit
from Cell Signaling. At least 500 PEC or PIN cells were evaluated to determine the percentage of proliferating (Ki-67-%), apoptotic (Apo-%) or cells in senescence
(Sen-%); * or ** indicates significant difference (p < 0.05) in the values between corresponding groups.
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Page 9 of 12but was unable to suppress MNU+hormone-stimulated
carcinogenesis. Even in p27+/- mice, a tendency for an
increase of PIN by 9cRA is obvious, although the differ-
ences in values with placebo-treated animals were not
significant. In all three p27 genotypes, the values of PIN
incidence are close in placebo- and 9cRA-treated ani-
mals. This data supports the results from clinical trials
where patients with an increased risk of prostate cancer
have been treated with beta carotene, retinol or other
antioxidants [36,37]. No efficacy on prostate cancer
reduction has been found, but an increase in lung can-
cer incidence has been observed that led to preliminary
termination of a clinical trial. One potential hypothesis
is that 9cRA or its metabolites are not efficacious in
highly proliferating cell systems, like PEC stimulated by
the above hormones. Our data from short-term experi-
ments where mice have been treated with testosterone +
9cRA supports this hypothesis. Another alternative is
that in long-term experiments 9cRA may protect PEC
from cell death after expiration of testosterone + estra-
diol stimulation (60-day releasing pellets). However, in
the long-term carcinogenesis study, 9cRA suppressed
the incidence and frequency of PIN in MNU-treated
mice, indicating that a lack of or decreased p27
Kip1 level
does not affect the efficacy of 9cRA in suppressing pros-
tate carcinogenesis. 9cRA is a ligand of both RARs a,b,g
and RXRs a,b,g, suggesting that it may affect various
cellular functions by receptor dependent mechanisms
[22,25,38]. By ICH we found that RARa and RXRa,
principal targets of retinoids and rexinoids, respectively,
are expressed in PEC of all three p27 genotypes, sug-
gesting a potential receptor-dependent mechanism of
9cRA-induced inhibition of PEC proliferation and carci-
nogenesis. An attempt was made to compare RARa and
RXRa positive cells in control- and 9cRA-treated ani-
mals in a carcinogenesis study (Table 3). However, no
difference in the percentage of receptor positive cells
was found (data not presented), suggesting receptor
independent mechanisms of 9cRA-induced inhibition of
prostate carcinogenesis [39]. It has been shown that reti-
noids, including 9cRA, at pharmacological doses prefer-
entially suppress cell proliferation and may also induce
cell differentiation [40]. Some previous studies have also
shown that retinoids may induce apoptosis as well,
depending on the tissue type and the dose used [9,15].
Our data obtained from the carcinogenesis study indi-
cates that 9cRA suppresses cell proliferation but is
unable to induce apoptosis. Interestingly, 9cRA did not
significantly affect cell proliferation in non-PIN cells,
which have low proliferative activity, but significantly
reduced proliferating cells in PIN of both p27+/- and
p27-/- mice, indicating that 9cRA may have the poten-
tial to suppress preferentially pre-malignant stages of
prostate carcinogenesis in men independent of the levels
of p27
Kip1 expression. Surprisingly, we found that in
addition to inhibition of cell proliferation, 9cRA can also
induce CS in both PIN and non-PIN associated PEC
(Table 5 and Fig. 2E-H). In a previous study on mam-
mary carcinogenesis, we compared the effect of 9cRA
and 4-HPR on CS in MNU-induced mammary tumors
and found that 9cRA has a superior role [24]. Data from
human prostate also suggest that senescent cells are fre-
quently detected in BPH and rarely in prostate cancer,
suggesting that malignant transformation of prostate
epithelial cells is associated with loss of the potential to
senesce [8,41].
Conclusion
Our data indicate that p27
Kip1 deficiency in PEC pro-
motes cell proliferation in an age-dependent manner
and increases cellular response to hormone stimulation.
p27
Kip1 haplo-insufficiency and deficiency stimulate
MNU-induced prostate carcinogenesis, suggesting that
PIN in human prostate lacking partial or total p27
Kip1
expression may have a higher potential to progress and
develop malignant phenotype than lesions with wild
type p27. The efficacy of 9cRA in suppressing PIN is
apparently not p27-dependent, indicating that in poten-
tial clinical trials, 9cRA may affect pre-malignant and
tumor cells that differentially expressed p27
Kip1.T h e
induction of CS by 9cRA in PIN suggests that this bio-
marker could be used as a potential biomarker of
response in clinical trials for the prevention and treat-
ment of prostate cancer.
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